Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
Notice that Interim Report 3 2022/23 will be published already on March 28, 2023
PHI changes the date for publication of Interim Report 3 2022/23 to March 28, 2023.
PHI creates a subsidiary for the anticipated EU patent concerning synthetic antibodies
PHI has decided to create a dedicated subsidiary to house the synthetic antibody patent family and facilitate its business potential.
CERN seminar: The Promise of Regenerative Medicine and AI
During this seminar, Peter Egelberg, Founder of PHI, will present the work carried out by PHI in the development of time-lapse cytometry instrumentation and software.
Technological developments in the rapidly evolving field of live-cell microscopy
Discover more about the developments in live-cell microscopy and how the HoloMonitor® technology is a gentle time-lapse imaging method for non-invasive, long-term and quantitative analysis of living cells.
BioStock: PHI catches eye of major investor
BioStock contacted Altium’s CEO Goran Dubravcic to learn more about their incentives to invest in PHI.
Swiss-based Altium acquires major stake in PHI
PHI announces that Altium S.A. recently acquired Formue Nord’s entire holdings in PHI of 2 416 679 shares and 1 491 362 TO 3 warrants and committed to exercise the obtained warrants.
The Scientist: Observing Cells in Their Natural State with Digital Holographic Cytometry
New blog article: Head over to The Scientist to read about observing cells in their natural state with digital holographic cytometry.
BioStock: PHI comments on the new senior positions in the company
BioStock reached out to Patrik Eschricht and Peter Egelberg to better understand the background behind the recent management shift.
India
PHI expands its global network to India
PHI has entered a business relationship with Medi Analytika India Pvt. Ltd. This new distributor will represent PHI in the large and growing Indian market and manage the full sales process and customer relations for the HoloMonitor® product portfolio.